LifeSemantics participates in 'CES 2023'... Reveals respiratory rehabilitation DTx solution 'Redpill Sumton'

Aerial view of LifeSemantics CES 2023 exhibition booth. [Photo by LifeSemantics]

[Asia Economy Reporter Lee Gwan-joo] Life Semantics announced on the 21st that it will participate in the world's largest IT and electronics exhibition, 'CES 2023,' held next month in Las Vegas, USA, to showcase the solution and technology of its respiratory rehabilitation digital therapeutics (DTx) 'Redpill Sumtun.'

It is estimated that there are more than 3 million respiratory rehabilitation patients in Korea, but only 200,000 actually receive treatment, and more than 50% of them are treated at large hospitals in Seoul. Domestic respiratory rehabilitation treatment is mainly conducted at large hospitals due to reasons such as cost, location, and lack of medical staff, and this situation is not much different in the United States.

Redpill Sumtun is a DTx that helps patients perform respiratory rehabilitation on their own. It was developed to improve the insufficient respiratory rehabilitation infrastructure and increase patient accessibility. It has various functions and systems to allow safe and comfortable respiratory rehabilitation at home, including ▲real-time monitoring of patients' exercise capacity through oxygen saturation and walking ability tests ▲automatic alarms and text guidance in case of emergencies or insufficient exercise during rehabilitation ▲adjustment of exercise amount according to patient health status using a metronome ▲real-time data transmission to medical staff.

Life Semantics will participate in the digital healthcare sector, setting up an exhibition booth in the integrated Korean pavilion within Eureka Park, and operate programs where visitors can indirectly experience chronic obstructive pulmonary disease (COPD) patients and directly try Redpill Sumtun. While promoting the effectiveness of Redpill Sumtun to various countries on-site, it is expected to grasp overseas DTx technology trends and confirm global demand for Redpill Sumtun.

Kwon Hee, Director of the DTx Division at Life Semantics, said, "DTx is already receiving much attention in the global healthcare market as it can manage patients' diseases more efficiently," adding, "We plan to enter the U.S. market in line with the completion of domestic approval for Redpill Sumtun, and through CES 2023, where we can officially showcase our differentiated technology to the global market, we will lay the foundation for expanding respiratory rehabilitation treatment infrastructure and full-scale overseas market entry."

This content was produced with the assistance of AI translation services.